Calamos Advisors
PRCT icon

Calamos Advisors’s Procept Biorobotics PRCT Stock Holding History

Calamos Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,142
Closed -$1.56M – 985
2025
Q2 		$1.56M Buy
+27,142
New +$1.53M 0.01% 654
2023
Q1 		– Sell
-81,103
Closed -$3.37M – 1193
2022
Q4 		$3.37M Buy
+81,103
New +$3.48M 0.02% 732

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Calamos Advisors's PRCT Position: Q3 2025 in Review

Calamos Advisors sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 27,142 shares — an estimated $1.56M sold.

Calamos Advisors first reported a position in PRCT in Q4 2022 and held it in 2 quarters. The position peaked at $3.37M in Q4 2022. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • Calamos Advisors reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • Calamos Advisors sold 27,142 Procept Biorobotics shares in Q3 2025, an estimated $1.56M.
  • Calamos Advisors first reported a position in Procept Biorobotics in Q4 2022 and held it in 2 quarters.
  • Calamos Advisors's Procept Biorobotics position peaked at $3.37M in Q4 2022.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on Calamos Advisors's 13F filing for Q3 2025, filed 20 Oct 2025.